Currently, N-glycan processing studies of the EGFR in NB are lacking, but studies using chemical inhibition of the N-glycosylation process or more directed changes to the N-glycans by overexpression or knockdown/out of glycosyltransferase in other cell lines have shown that modified N-glycosylation alters EGFR activation and downstream signaling [23,25–27,31]. The gene discussed is EGFR; the disease is neuroblastoma.